BMS Highlights Data from the P-I/II Study of Krazati Plus Cetuximab to Treat Locally Advanced or Metastatic Colorectal Cancer at the AACR 2024
Shots:
- BMS has highlighted results from the P-I/II (KRYSTAL-1) trial arms assessing the safety & effectiveness of Krazati + cetuximab for previously treated KRASG12C mutated locally advanced or metastatic colorectal cancer (CRC) patients at the AACR 2024 and published in Cancer Discovery
- The study, with a median follow-up of 11.9mos. among 94 patients, demonstrated ORR of 34%, mPFS of 6.9mos., mOS of 15.9mos., mDoR of 5.8mos. and 85% of patients experienced disease control
- In Feb 2024, the US FDA accepted and granted priority review to the company’s sNDA of Krazati + cetuximab for previously treated KRASG12C-mutated locally advanced or metastatic CRC patients with the decision anticipated in Jun 2024
Ref: BMS | Image: BMS
Related Posts:- BMS Reports Results from the P-III (KRYSTAL-12) Study of Krazati for the Treatment of Non-Small Cell Lung Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
